Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications measuring nutrient reduction benefits policy analysis using linked non market valuation
… it compares to comparators); and clinical effectiveness. Non-clinical HTA domains, which mainly involve cost, economic … evidence-generation plan. The ultimate success of JCAs and market access in Europe will increasingly hinge on including … Assessment in the European Union and the Inflation Reduction Act in the United States Navigating EU Joint …
… real-world outcomes, and resource use in patients with non-MSI-high or mismatch repair proficient advanced …
ISOQOL 2023 Share on: Wednesday, October 18 - Saturday, October 21, 2023 Conference website 30 Years of ISOQOL: Quality of Life – making it relevant. Research and presentations by RTI Health Solutions experts are on the program for ISOQOL 2023. An …
… contributed by: Shahnaz Khan, MPH , Executive Director, Market Access and Outcomes Strategy at RTI Health Solutions … providing the following unbiased, factual, accurate, and non-misleading information. Information about the indications … from Phase 1, Phase 2, and Phase 3 studies (peer-reviewed publications; congress abstracts, posters, and presentations; …
… and practices for multiple vaccines currently on the market, and consumers’ knowledge, attitudes, and perceptions … milestones across the studies, while meeting deadlines for publications. OUR APPROACH We assembled a core team of …
Webinar: Characteristics of Recent PRO Labeling by the FDA and EMA for Oncology Drugs Share on: Wednesday, March 13 - Thursday, March 14, 2019 Watch the Recording Trends in EMA and FDA Labeling Based on Patient-Reported Outcomes (PROs) A recent review of …
… You’ll hear our experts in patient-centered outcomes and market access strategy have a conversation about their … failures, and the lessons we've learned Related Services Market Access and Outcomes Strategy Patient-Centered Outcomes …
… often respond to these unsolicited requests from payers using evidence requirements outlined in the Academy of … before an approval decision and accelerate their time to market launch. Pre-approval communication with payers may … the following types of “unbiased, factual, accurate, and non-misleading” information: Product information such as drug …
… our clients develop strategies in the infectious disease market and to develop and gain market access for products to treat infectious diseases and … of patient preferences for treatment options Meta-analysis studies Observational studies Patient-reported …
… be clearly specified in a study protocol and statistical analysis plan and should include information about the amount …